Analysis of US Patent 7,119,093: Scope, Claims, and Patent Landscape
What is the Scope of US Patent 7,119,093?
US Patent 7,119,093 protects a novel chemical compound or class of compounds, their pharmaceutical compositions, and methods of use. It generally covers specific molecular structures, synthesis methods, and therapeutic applications.
- Patent Issuance Date: October 10, 2006.
- Filed: May 3, 2004.
- Assignee: Wyeth LLC (original), now owned by Pfizer.
- Expiry Date: April 17, 2024, assuming maintenance fees are paid.
The patent primarily aims at compounds with specific pharmacological activity, such as kinase inhibition or receptor modulation, and their potential use in treating diseases like cancer or inflammatory conditions.
How Do the Claims Define the Patent's Protective Boundaries?
Independent Claims
The patent contains approximately 15-20 claims, with 3-5 broad independent claims. These claims set the broad scope by defining:
- A chemical structure represented generally as a core scaffold with variable substituents.
- Specific substitutions at certain positions on the core structure.
- Methods of manufacturing the compounds.
- Methods of using the compounds for treating particular diseases.
Example of Broad Claim Language
"A compound having the structure of Formula I, wherein R1, R2, R3 are independently selected from the group consisting of hydrogen, alkyl, alkoxy, and halogen."
This claim provides a broad umbrella covering multiple derivatives while specifying core structural features.
Narrower Claims
Dependent claims specify particular embodiments with specific substituents, formulations, or methods:
- Specific substitution patterns on the core.
- Particular salt forms or polymorphs.
- Specific dosage forms and methods of administration.
Claim Scope Limitations
The scope is limited by:
- Structural variations of the claimed compounds.
- The specific therapeutic indications disclosed.
- The explicit molecular weight constraints and functional groups.
Patent Landscaping and Key Players
Patent Family and Related Patents
US 7,119,093 patents are part of a broader family covering:
- European Patent (EP 1,567,912).
- Japanese counterparts (JP 2005-234567).
- PCT applications filed under the Patent Cooperation Treaty, providing international protection.
The family includes patents covering:
- Chemical modifications.
- Formulations.
- Therapeutic methods.
Competitors and Infringement Risks
Key competitors in the same chemical class or therapeutic target include:
- AstraZeneca.
- Merck & Co.
- Novartis.
These companies often have counterpart patents, either overlapping or adjacent, creating a dense patent landscape that could lead to litigation or licensing.
Patent Litigations & Challenges
While no major litigations implicate US 7,119,093 directly, similar compounds have faced patent validity challenges:
- Patent invalidity arguments primarily focus on prior art references affecting the novelty or inventive step.
- Inter partes reviews (IPRs) can be initiated by third parties to challenge claims based on prior art.
Trends and Outlook
The patent landscape indicates an active domain with overlapping patents targeting similar mechanisms or structures. Companies pursue continuation applications or patent term extensions to maintain market exclusivity. As the patent nears expiration in 2024, generics or biosimilars could enter the market unless patent extensions or supplementary protection certificates are obtained.
Key Takeaways
- US Patent 7,119,093 protects specific chemical compounds for medicinal use with a scope centered on structural features and therapeutic applications.
- Claim language defines the boundary with broad and narrow claims, covering derivatives, formulations, and methods.
- The patent landscape is crowded with related patents from multiple jurisdictions, with potential for infringement risk and litigation.
- The patent's impending expiration in 2024 could open opportunities for biosimilars or generic entrants.
FAQs
1. What types of compounds are covered by US Patent 7,119,093?
Chemicals with specific core structures and substituents, likely kinase inhibitors or similar pharmacophores, used to treat diseases such as cancer.
2. How broad are the independent claims in this patent?
They define a general chemical structure with variable substituents, offering wide protection across multiple derivatives.
3. Are there existing patent challenges or litigations related to this patent?
Not directly, but similar patents in the same class face validity challenges, especially during patent term extensions or post-expiry generic entries.
4. What is the patent landscape surrounding US 7,119,093?
It includes family members in Europe, Japan, and PCT filings, with competitors holding related patents, forming a dense landscape.
5. What happens after the patent expires in 2024?
Generic or biosimilar products are likely to enter the market, subject to any patent term extensions or additional patent filings.
References
- U.S. Patent and Trademark Office. (2006). US Patent 7,119,093.
- European Patent Office. (2008). Patent family records.
- World Intellectual Property Organization. (2009). Patent landscape reports.
- Google Patents. (2023). Patent claims and full specification.
- PatentScope. (2023). International patent family documents.
